Tejon Ranch 3Q 2026: Revenue $22.61M, EPS $0.12 — 10-Q Summary

Tejon Ranch reported 3Q 2026 revenue of $22.61M, up 88.9% YoY, and EPS of $0.12, up 100% YoY. Growth was driven by improved farming results, multifamily lease-up, and mineral resources, partially offset by higher taxes and lower joint-venture earnings.

Original reporting
Published Nov 5, 2026, 7:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tejon Ranch 3Q 2026: Revenue $22.61M, EPS $0.12 — 10-Q Summary — source image
Decision brief

The 30-second read

$TRCBullishLow
01

Why it matters

The earnings beat provides fresh data for valuation models and may trigger short‑term buying interest.

02

Market read

First‑time disclosure of Q3 results for a micro‑cap; modest relevance for traders focused on small‑cap earnings beats.

03

What to watch

Potential volatility from weather‑related crop yields and commodity price swings could offset the earnings boost.

Relevance 6/10Novelty 6/10Timing: post‑market release today

Background

Tejon Ranch Co filed its Form 10‑Q for Q3 2026, reporting revenue and earnings growth across multiple segments.

Company-level read

Ticker impact

$TRCBullishMedium confidence
Context

Q3 2026 revenue of $22.61M and EPS of $0.12 beat prior-year figures, marking the first public disclosure of the quarterly results.

Expected impact

likely modest upward pressure as the market prices in the earnings beat and improved segment performance

Evidence & confidence

The company posted a near‑100% YoY increase in net income and EPS, but absolute numbers are small for a micro‑cap, limiting upside.

Market effects

Better farming and mineral revenue trends may signal strength for similar agribusiness and resource‑extraction peers.

Limited to the niche agribusiness sector; no broad regional effect.

Low; the company is a small cap with niche exposure.

Counterpoint

Given the modest absolute size, the earnings beat may be already priced in; upside could be limited.

Key entities

  • Tejon Ranch Co

    Agribusiness and real‑estate operator reporting Q3 2026 results.

Related articles

$TRCMed

Tejon Ranch Q3 Earnings Call Highlights

Tejon Ranch (TRC) reported Q3 revenue growth in mineral resources and multifamily sectors, with operating income up 58%. Key projects, including a casino and residential developments, are advancing. The company has $74.4M in liquidity and $94.4M in debt. Management addressed investor concerns about costs and debt reduction, emphasizing cash flow generation and disciplined capital deployment.

$TRCMed

TEJON RANCH CO. ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

TEJON RANCH CO (TRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TEJON RANCH CO. ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS TEJON RANCH, California - November 5, 2026 - Tejon Ranch Co. (NYSE: TRC), (“Tejon” or the “Company”), a diversified real estate, land and agribusiness company, today announced financial results for the th

$TRCMed

Tejon Ranch (TRC) Q2 2026 Earnings Call Transcript

Tejon Ranch Co. (TRC) reported Q2 2026 consolidated revenue of $14.3M, up from $8.3M, and net income of $2.6M ($0.10/share). Adjusted EBITDA rose 47% to $8.4M. Land sales to a 60% owned joint venture contributed $6.9M revenue and $2M profit. Liquidity was $79.2M at June 30, 2026.

$TRCMed

TEJON RANCH CO. ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

TEJON RANCH CO (TRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TEJON RANCH CO. ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS TEJON RANCH, California—August 6, 2026 - Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate, land and agribusiness company, today announced financial results for the second

$RVMDHighAI 8/10

105 Hedge Funds Own This Cancer Drug Stock After a Breakthrough — Is Something Bigger Coming?

Revolution Medicines (RVMD) ranked 6th in a list of top healthcare and insurance stocks to buy after the 2026 Democratic midterm sweep, with 105 hedge funds owning it. The company's cancer drug, Rasonque, received US approval and generated $197.6M in net product revenue in Q3 2026. Analysts note potential legislative changes could impact healthcare sector performance.